Retatrutide is a “triple G” (GLP-1, GIP, glucagon) receptor agonist showing ground-breaking potential for obesity, with phase 2/3 trials demonstrating up to 28.7% body weight loss over 68 weeks. It significantly improves metabolic health, including blood sugar control, blood pressure, fat reduction in the liver, and increased energy metabolism. Retatrutide if used correctly is undoubtedly the most powerful peptide ever developed for fat loss.

Tesamorelin isn’t just another peptide it’s one of the most researched growth hormone releasing analogues available today. Originally developed as a medical therapy to combat visceral fat accumulation in HIV patients, it has since captured the attention of the bodybuilding community for its dual power to lean out stubborn fat while preserving and even supporting muscle tissue.

5-Amino-1-methylquinolinium (5-Amino-1MQ) is a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT) an enzyme linked to metabolic rate regulation, fat storage, and cellular energy balance. When NNMT activity is high fat storage pathways become more active and metabolic rate slows, making fat loss harder.  5-Amino-1MQ also promotes mitochondrial biogenesis the creation of new, healthy mitochondria and optimizes the performance of existing mitochondria. 5-Amino-1MQ supports fat oxidation while protecting muscle tissue, even during caloric restriction.

CJC – 1295 and Ipamorelin: Combining CJC-1295 and ipamorelin stimulates the pituitary gland to increase natural growth hormone production, which can enhance lipolysis (fat breakdown) and improve body composition over time. CJC-1295 is a growth hormone-releasing hormone (GHRH) analog that extends the duration of growth hormone secretion. Ipamorelin is a selective ghrelin receptor agonist that creates a clean, sharp pulse of growth hormone release. Using them together produces a larger, more sustained growth hormone pulse than either peptide would achieve independently.

AOD9604 is a peptide derived from the C-terminal fragment of the human growth hormone. It consists of a specific sequence of amino acids that primarily targets fat loss by enhancing the breakdown of fat and inhibiting lipogenesis. The AOD peptide stimulates lipolysis, the breakdown of fats into free fatty acids, and prevents the formation of new fat deposits. This dual action may be beneficial for individuals seeking to enhance their fat loss efforts without directly affecting muscle tissue or causing significant changes in glucose metabolism.

MOTS-c is a mitochondrial-derived peptide primarily studied for its potential to regulate metabolism, improve insulin sensitivity, and fight aging-related diseases. It targets skeletal muscle to boost glucose metabolism, similar to metformin, and has shown promise in reducing obesity and improving athletic performance in animal studies.

Cagrilintide is a synthetic, long-acting amylin analogue peptide developed by Novo Nordisk as a potential treatment for obesity and related metabolic conditions. Cagrilintide’s power lies in its ability to mimic amylin, a hormone that works alongside insulin to regulate food intake and blood sugar. By engineering Cagrilintide as a long-acting amylin analog, researchers have created a peptide that can deliver these effects steadily with once-weekly dosing. Cagrilintide delays how quickly food leaves the stomach, which helps promote a longer-lasting feeling of fullness after meals and it also acts on the brain’s satiety centers and by increasing satiety signals, it naturally lowers calorie consumption without relying on willpower alone so losing weight becomes easier.

Adipotide, also known as FTPP (Fat-Targeted Proapoptotic Peptide), is a synthetic research peptide developed to target and reduce body fat by acting directly on the blood vessels that nourish fat cells. Unlike traditional fat burners that rely on stimulating metabolism or appetite suppression, Adipotide works through a vascular mechanism, cutting off the blood supply to fat tissue, ultimately leading to its breakdown and removal from the body.

SS-31 is a peptide that accumulates in the inner mitochondrial membrane and modulates the mitochondrial function. It then regenerates adenosine triphosphate (ATP) production, which brings the energy levels back up. SS-31 is primarily a mitochondria-targeted peptide that is responsible for repairing dysfunctional mitochondria. Therefore, its mechanism of action mostly revolves around modulating mitochondrial biogenesis and function which is essential to burn fat.

SLU-PP-332 emerged from research conducted at Saint Louis University School of Medicine, where scientists set out to create a compound that could activate the same metabolic pathways triggered by aerobic exercise. The result was a small molecule that acts as a potent agonist for oestrogen-related receptors, specifically targeting ERR alpha, beta, and gamma subtypes with varying degrees of potency. When SLU-PP-332 binds to these receptors, it initiates a cascade of genetic changes that mirror what happens during sustained aerobic activity. The compound essentially flips genetic switches that your body normally only activates after weeks of consistent endurance training. The practical implication here matters significantly. Unlike compounds that work primarily through appetite suppression or hormonal manipulation, SLU-PP-332 generates its effects by changing how your muscles use fuel at a fundamental level. Your body starts burning fatty acids preferentially, even at rest, because the genetic programming for endurance metabolism has been activated.